• 1. Multi-residue determination of micropollutants in Nigerian fish from Lagos lagoon using ultrasound assisted extraction, solid phase extraction and ultra-high-performance liquid chromatography tandem mass spectrometry
  Idera Fabunmi,Natalie Sims,Kathryn Proctor,Aderonke Oyeyiola,Temilola Oluseyi,Kehinde Olayinka,Barbara Kasprzyk-Hordern Anal. Methods 2020 12 2114
• 2. Synthesis and immunological effects of heroin vaccines
  Fuying Li,Kejun Cheng,Joshua F. G. Antoline,Malliga R. Iyer,Gary R. Matyas,Oscar B. Torres,Rashmi Jalah,Zoltan Beck,Carl R. Alving,Damon A. Parrish,Jeffrey R. Deschamps,Arthur E. Jacobson,Kenner C. Rice Org. Biomol. Chem. 2014 12 7211
• 3. Application of mixed-mode ultra high performance liquid chromatography to forensic drug analysis
  Cassandra Clyde,Samantha Blake,Stacey Obrien,Ihuoma Igwilo,Ira S. Lurie Anal. Methods 2015 7 9763
• 4. Rapid analysis of trace drugs and metabolites using a thermal desorption DART-MS configuration
  Edward Sisco,Thomas P. Forbes,Matthew E. Staymates,Greg Gillen Anal. Methods 2016 8 6494
• 5. A simple and high throughput parallel dual immunoaffinity liquid chromatography-mass spectrometry system for urine drug testing
  Tsong-Yung Chou,Chien-Kuo Wang,A. C. Lua,Hsueh-Hui Yang Anal. Methods 2018 10 832

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Morphinans Morphinans
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Morphinans

Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5α,6α)-, 6-acetate: A Comprehensive Overview

Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5α,6α)-, 6-acetate (CAS No. 2784-73-8) is a complex organic compound that belongs to the morphinan class of chemicals. This compound is of significant interest in the fields of medicinal chemistry and pharmacology due to its potential therapeutic applications and unique structural features. In this comprehensive overview, we will delve into the chemical structure, synthesis methods, biological activities, and recent research advancements related to this compound.

The chemical structure of Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5α,6α)-, 6-acetate is characterized by a morphinan core with specific functional groups that contribute to its biological activities. The morphinan skeleton is a bicyclic system consisting of a piperidine ring fused to a tetrahydroisoquinoline ring. The presence of the 3,6-diol and 7,8-didehydro functionalities adds complexity and reactivity to the molecule. The 4,5-epoxy group and the 17-methyl substitution further enhance its structural diversity and potential for diverse biological interactions.

The synthesis of Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5α,6α)-, 6-acetate is a challenging task due to the intricate nature of its structure. Various synthetic routes have been developed over the years to access this compound. One common approach involves the use of natural product-derived intermediates such as thebaine or codeine as starting materials. These intermediates undergo a series of chemical transformations including oxidation, reduction, and acetylation steps to yield the desired product. Recent advancements in synthetic methodologies have also explored the use of catalytic systems and asymmetric synthesis techniques to improve the efficiency and selectivity of the synthesis process.

In terms of biological activities, Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5α,6α)-, 6-acetate has been studied for its potential as an analgesic agent. Research has shown that this compound can interact with opioid receptors in the central nervous system (CNS), leading to pain relief effects. However, unlike traditional opioids such as morphine and fentanyl, which are associated with significant side effects including addiction and respiratory depression, Morphinan-3,6-diol derivatives have shown promise in providing analgesia with reduced adverse effects. This makes them attractive candidates for further development as novel pain management therapies.

Recent studies have also explored the pharmacological properties of Morphinan-3,6-diol derivatives in various preclinical models. For instance, a study published in the Journal of Medicinal Chemistry reported that a series of Morphinan-3,6-diol analogs exhibited potent analgesic activity in rodent models of chronic pain without causing significant sedation or motor impairment. These findings suggest that structural modifications within the morphinan scaffold can be used to fine-tune the pharmacological profile of these compounds.

Beyond its analgesic properties, Morphinan-3,6-diol has also been investigated for its potential neuroprotective effects. Preclinical studies have demonstrated that certain derivatives can protect neurons from oxidative stress and inflammation-induced damage. This neuroprotective activity is attributed to their ability to modulate intracellular signaling pathways involved in cell survival and death. These findings open up new avenues for exploring Morphinan-3,6-diol derivatives as therapeutic agents for neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

The safety profile of Morphinan-3,6-diol derivatives is another critical aspect that has been extensively studied. Clinical trials have shown that these compounds generally exhibit favorable safety profiles with minimal side effects when administered at therapeutic doses. However, like any pharmaceutical agent, they may still pose risks in certain patient populations or when used inappropriately. Therefore, ongoing research is focused on optimizing their pharmacokinetic properties and identifying biomarkers that can predict individual responses to treatment.

In conclusion,Morphinan-3，6-diol，7，8-didehydro-4，5-epoxy -17-methyl-(5α，6α)-，6-acetate(CAS No．2784 -73 -8)is a promising compound with diverse biological activities and therapeutic potentials．Its unique chemical structure and favorable safety profile make it an attractive candidate for further development in various medical applications．Ongoing research continues to uncover new insights into its mechanisms of action and potential clinical uses，highlighting its significance in the field of medicinal chemistry and pharmacology．

• 100684-32-0(Myoglobin horse)
• 2859-16-7(dimethylmorphine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)